Targeting the ICOS/ICOS-L pathway in a mouse model of established allergic asthma disrupts T follicular helper cell responses and ameliorates disease.

However, consistent with decreased pulmonary inflammation (Figure 4 A), total numbers of IL‐13 + CD4 + T cells and IL‐13 + ILC2s showed a trend towards reduction following α‐ICOS‐L treatment (Figure 6 C).

also in 53,322 other papers